FDA Announces Approval of Information Collection on Direct-to-Consumer Prescription Drug Ads

Summary

The Food and Drug Administration (FDA) has announced that it has received approval from the Office of Management and Budget (OMB) to collect information on the impact of ad exposure frequency on perception and mental processing of risks and benefits in direct-to-consumer prescription drug ads, as mandated by the Paperwork Reduction Act of 1995.